Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause‐specific mortality
- 17 January 2013
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 73 (9) , 905-912
Abstract
BACKGROUND: ETS‐related gene (ERG) protein is present in 40–70% of prostate cancer and is correlated with TMPRSS2‐ERG gene rearrangements. This study evaluated ERG expression at radical prostatectomy to determine whether it was predictive of earlier relapse or prostate cancer‐specific mortality (PCSM).METHODS: One hundred patients who underwent radical prostatectomy at Virginia Mason in Seattle between 1991 and 1997 were identified. Recurrence was confirmed by tissue diagnosis or radiographic signs. PCSM was confirmed by death certificates. Thirty‐three patients with metastases or PCSM were matched to patients without recurrence at a 1:2 ratio. Paraffin embedded tissue was stained with two anti‐ERG monoclonal antibodies, EPR3864 and 9FY. Nuclear expression intensity was evaluated as present/absent, on a 4‐point relative intensity scale, and as a composite score (0–300).RESULTS: Mean follow‐up was 10.26 years. The two antibodies were highly correlated (P < 0.0001). Patients with higher ERG expression intensity and composite scores were significantly more likely to develop biochemical relapse, metastases, and PCSM. Kaplan–Meier survival curve analysis for the composite score of ERG expression revealed a significant association between higher ERG expression (EPR3864) and shorter PCa‐specific survival (P = 0.047).CONCLUSIONS: While the presence of ERG expression at the time of surgery was not predictive of earlier relapse or PCSM, the relative intensity and composite score for ERG expression was prognostic for the development of biochemical relapse, metastases, and PCSM. Quantitative ERG scoring may be useful to identify patients who would benefit from adjuvant treatment or closer follow‐up, allowing more accurate individual patient treatment plans. Prostate 73: 905–912, 2013.Keywords
Funding Information
- Canary Foundation
- Pacific Northwest Prostate Cancer SPORE (P50CA097186)
- Prostate Cancer Foundation
This publication has 18 references indexed in Scilit:
- The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2012
- ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortalityEuropean Journal of Cancer, 2012
- ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancerLaboratory Investigation, 2012
- ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodiesProstate Cancer and Prostatic Diseases, 2012
- ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal TherapyClinical Cancer Research, 2011
- Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomasLaboratory Investigation, 2011
- Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic AdenocarcinomasAmerican Journal of Surgical Pathology, 2011
- Androgen Regulation of ETS Gene Fusion Transcripts in Prostate Cancer2011
- Antibody-Based Detection of ERG Rearrangement-Positive Prostate CancerNeoplasia, 2010
- Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate CancerClinical Cancer Research, 2009